According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a core, but underused, treatment approach to reduce migraine frequency, severity, and duration in high-frequency episodic migraine and CM patients. Treatment options are primarily a mix of off-label and approved AEDs, beta blockers, and TCAs, as well as Botox (Allergan\u2019s onabotulinumtoxinA), one of the few agents approved specifically for CM. However, given the heterogeneous patient population, chronic prophylactic treatment is individualized and can evolve over time. Understanding patient pathways and drivers of treatment decision-making is key for new players entering this large but mostly generic market.<\/p>\n
QUESTIONS ANSWERED<\/p>\n
What factors do U.S. physicians look for when determining if a patient is fit for prophylactic treatment?
\nWhat are the drivers and constraints influencing physicians\u2019 treatment decisions for migraine prophylaxis?
\nHow long does it take for patients to progress between lines of therapy? How are patients being treated across different lines of therapy?
\nTo what extent is polypharmacy prescribed for prophylaxis, and what are physicians\u2019 preferred drug class combinations?
\nHow has the use of key prophylactic therapies changed in the past year, and what changes do physicians expect in their prescribing of these drugs in one year?
\nHow do Botox (Allergan) and Trokendi XR (Supernus) compete in the generics-heavy migraine market? What drivers and constraints will aid or restrict their future use?
\nPRODUCT DESCRIPTION<\/p>\n
Current Treatment:<\/p>\n
Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand use so that you can understand each brand\u2019s performance and improve or defend your competitive position.<\/p>\n","protected":false},"template":"","class_list":["post-390911","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-migraine","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390911\/revisions"}],"predecessor-version":[{"id":394035,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390911\/revisions\/394035"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}